Taysha Gene Therapies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TSHA Nasdaq 8731 https://tayshagtx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Taysha Gene Therapies Inc

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome - Jun 5th, 2023 12:00 pm
Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate - May 19th, 2023 4:54 pm
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting - May 19th, 2023 12:00 pm
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript - May 16th, 2023 3:41 pm
Q1 2023 Taysha Gene Therapies Inc Earnings Call - May 12th, 2023 2:15 pm
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 11th, 2023 8:01 pm
Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11 - May 4th, 2023 12:00 pm
Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting - Apr 27th, 2023 8:52 pm
Even after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past year - Apr 15th, 2023 12:24 pm
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Call Transcript - Mar 30th, 2023 10:08 am
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Mar 28th, 2023 8:01 pm
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28 - Mar 15th, 2023 8:01 pm
How patients' families pushed rare-disease therapy to cusp of clinical trial — until biotech's cash halted progress - Feb 14th, 2023 10:32 pm
A Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider increased their holdings by 28% last year - Feb 8th, 2023 10:42 am
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook - Jan 31st, 2023 9:01 pm
Biotech signals potential pullback from 200-job Durham plant - Jan 24th, 2023 7:32 pm
Dallas-based Taysha Gene Therapies names board chair as new CEO - Dec 19th, 2022 7:05 pm
Taysha Gene Therapies Announces Executive Leadership Changes - Dec 16th, 2022 11:19 pm
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now - Dec 1st, 2022 2:55 pm
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit - Nov 29th, 2022 9:01 pm